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There is currently much excitement surrounding the rapidly growing discipline of synthetic biology,
which utilizes the design and construction principles of engineering to develop, evolve and standardize
biological components and systems. This systematic approach to improving and increasing the
programmability and robustness of biological components is expected to lead to the facile assembly of
artiﬁcial biological components and integrated systems that enable innovative approaches to solving a
wide range of societal challenges. Here we discuss the current state of the art and outline the next wave
of synthetic biology: integrating individual components into systems.
What is synthetic biology?
The polish scientist Waclaw Szybalski envisaged the possibilities
offered by the ﬁeld of molecular biology upon its maturation in
1974: “Up to now we are working on the descriptive phase of molec-
ular biology.… But the real challenge will start when we enter the
synthetic biology phase of research in our ﬁeld. We will then devise
new control elements and add these new modules to the existing
genomes or build up wholly new genomes. This would be a ﬁeld
with the unlimited expansion potential…”.1 The increasingly facile
and rapidly decreasing cost of DNA synthesis and sequencing has
made the above a reality today. This, combined with an increased
understanding of biological systems (especially bacterial), has
allowed genetic-level modiﬁcation of living organisms. Advances
in recombinant DNA technologies have led to the host organism
being increasingly viewed as a chassis, with its components
utilised for the replication or overproduction of non-native genes,
proteins or small molecules. Biological material, especially DNA
and proteins, can therefore be considered components that may
School of Chemistry, University of Southampton, Southampton, UK SO17
1BJ. E-mail: ali1@soton.ac.uk
Ali Tavassoli
Ali is a lecturer in chemical
biology at The University of
Southampton. He is the recipi-
ent of the European Association
for Chemical and Molecular Sci-
ences’ silver medal for European
Young Chemist, and a Career Es-
tablishment Award from Cancer
Research UK. He has a multidis-
ciplinary background in synthetic
chemistry and molecular biology.
His lab’s research interests are
at the interface of chemistry and
biology; developing high through-
put tools, screening methodologies and uncovering compounds
that tackle diseases through inhibition of speciﬁc protein-protein
interactions. They are also active in the new ﬁeld of synthetic biology.
For more information see the Tavassoli group website.
be readily assembled within the bacterial chassis, and utilised
to produce a system whose functionality can be designed and
predicted.A good analogy is the computer industry, and the ability
to assemble a device from individual components (processor, hard
drive, monitor etc…) that interface with each other and function
together as a single unit. Synthetic biologists wish to design and
construct (de novo), or evolve standardised biological components
that functionally interface with each other with similar ease, and
can be rationally combined to produce a predetermined outcome.
The synthetic biology community is composed of biologists,
chemists and engineers. The diverse background of its proponents
has lead to two main branches emerging;2 commonly referred
to as top-down and bottom-up synthetic biology. Top-down
synthetic biologists aim to reprogram cellular behaviour through
introduction of non-native genes and reconﬁguration of the
gene expression networks. The overall intent is to simplify the
creation of complex regulatory networks by utilizing engineering
tools and mathematical models developed in systems biology,
bioengineering and biotechnology. Such networks can then be
constructed and programmed (analogous to a computer) to carry
out a designated function. Bottom-up synthetic biology utilizes
ﬁrst principles for the de novo construction of synthetic genomes
and non-natural molecules that behave analogously to their
counterparts in living systems. This approach utilizes the tools
of chemistry and biochemistry, with the creation of artiﬁcial life
being a long-term goal.
We begin by describing the achievements of the ‘ﬁrst wave’ of
synthetic biology: the construction of genetic units and modules,
engineering of biosynthetic pathways and networks and work
towards minimal genome organisms and chassis. Rather than give
a detailed and comprehensive discussion of all projects, we use
a few examples to illustrate the achievements of the ﬁeld. We
ﬁnish by detailing our thoughts on the next wave of synthetic
biology, which is expected to combine and utilize these basic parts
to construct complicated and complex systems.
Components and modules
One of the deﬁning goals of synthetic biology is the application
of engineering principles to biological systems to develop and
construct networks and pathways that behave in a predictable
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manner.3 One can envisage synthetic gene networks constructed
to emulate digital circuits and devices, potentially allowing
programming of cellular behaviour using the same principles as
modern computing. One of the earliest examples of this approach
is the construction of a genetic toggle switch in E. coli, based
on the predictions of a simple mathematical model.4 The switch
is composed of two repressors and two constitutive promoters
(Fig. 1), with each promoter being inhibited by the repressor
that is transcribed by the opposing promoter. The switch is thus
ﬂipped between stable states by either inducer (transient chemical
or thermal induction, depending on the promoter). The design of
the system may seem simplistic from a molecular biology point
of view; however, the strength of this approach is the utilization
of mathematical models and engineering principles to ensure the
bistability of the switch.4
Fig. 1 Toggle switch design. Repressor A inhibits transcription of
repressor B by targeting promoter A. Inducer A binds repressor A,
switching on promoter A and transcription of repressor B. Inducer B
inhibits repressor B, switching on transcription of repressor A and the
reporter gene. Thus the switch can be ﬂipped between stable states using
inducer A or inducer B. The behaviour of the toggle switch and the


















, whereU is the concentration of repressor A, and
V is the concentration of repressor B, a1 is the effective rate of synthesis
of repressor A and a2 is that for repressor B. b is the cooperativity of
repression of promoter B and g is that for promoter A.
Another example of a module is a genetic oscillator, of which
several examples exist. An early example used three transcriptional
repressors in a negative feedback loop,5 with the mathematical
model developed to predict transcriptional regulation behaviour
being particularly elegant. In this model, the repressor proteins
and their corresponding mRNA concentrations are treated as
continuous, dynamic variables. Variations in factors such as the
dependence of the transcription rate on repressor concentration,
the translation rate, and the decay rate of the protein and mRNA,
result in one of two solutions: either the system converges towards
a steady state, or the systembecomes unstable, leading to sustained
limit-cycle oscillations. The model indicated that oscillations are
favoured in systems with strong promoters coupled to efﬁcient
ribosome-binding sites, with comparable protein and mRNA
decay rates. The network was therefore constructed to this model,
using hybrid promoters (to ensure transcriptional strength and
tightness) and a carboxy-terminal tag that reduces the half-life of
the repressor proteins, bringing it in line with that for mRNA. The
oscillator network periodically induces the production of green
ﬂuorescent protein and interestingly, as the periods of oscillation
were slower than the cell-division cycle, the oscillator state seems
to be transmitted fromgeneration to generation.Other examples6,7
of synthetic oscillators have introduced more robust and tunable
oscillators (Fig. 2), and a tunable synthetic oscillator that functions
within mammalian cells.8
Fig. 2 A dual-feedback circuit oscillator. Three copies of a hybrid
promoter (plac/ara-1—made up of the activation operator site from the
araBAD promoter and the repression operator site from lacZYA) drive
the expression of araC, lacI and GFP genes, forming negative and
positive feedback loops. The promoter is activated by the AraC protein
in the presence of arabinose and repressed by the LacI protein in the
absence of isopropyl -D-1-thiogalactopyranoside (IPTG). The promoters
are activated by the addition of arabinose and IPTG to the growthmedium.
The increasedproductionofAraC in the presence of arabinose activates the
positive feedback loop; the concurrent increase in LacI, however, results
in activation of the negative feedback loop. The differential activity of
the two feedback loops leads to oscillatory behaviour by the circuit. The
oscillatory period is tunable (from around 15 min to 60 min) by varying
the IPTG and arabinose levels.
Another key component of digital circuits and computing is a
counter, a simple cellular equivalent of which has recently been
reported.9 The genetic counter can count up to three induction
events, allowing counting of varied, user-deﬁned inputs. The ever-
increasing synthetic gene circuit components have enlarged the
molecular toolbox available to synthetic biologists and bioengi-
neers, allowing the construction of cellular systems of increasing
complexity and sophistication.6,9 Despite these rapid advances in
synthetic genomics, assembling such networks with predictable
functions remains very challenging and requires considerable
retroﬁtting and ﬁne-tuning of parts for the system to function
as intended. The advancement of this ﬁeld and the realization
of its long-term goals are therefore dependant on increasing the
predictability and decreasing the amount of ﬁne-tuning required
to construct functional networks.10 Another major step forward
would be combining these components within the same chassis, to
produce a multi-component, multi-functional synthetic network.
Engineering biosynthetic networks
Microbial hosts have long been utilised as chassis for the produc-
tion of non-native proteins via singular transgenes. An example
of traditional genetic engineering is the introduction of the gene
that codes for human insulin into E. coli for the production of
transgenic protein.11 The integration and engineering of multiple
pathways into a bacterial host would enable a similar approach to
be taken for the production of complex natural products. Coupling
multiple enzymes to create a metabolic pathway allows circum-
navigation of much of the problems associated with chemical
synthesis of complex natural products, chemical intermediates or
even small molecules; enzymes catalyse in a single step what may
require multiple steps and puriﬁcations by synthetic chemistry.
Given the increasingly important role played by natural products
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 24–28 | 25
(such as Taxol andVancomycin) in healthcare, there is tremendous
potential in developing new biosynthetic pathways for the rapid
production of complex compounds from simple, inexpensive
starting materials. The synthetic biology approach to engineering
suchmetabolic pathways is to focus on the design and construction
of core components, with predictable, tunable function, that can
be assembled into larger integrated systems. This is particularly
challenging, given the nonlinear nature of biological components
and the unpredictability of the interactions of new components
with biological systems.
A successful implementation of this approach is the produc-
tion of artemisinic acid, a precursor of the antimalarial drug
artemisinin (Fig. 2) in engineered E. coli12 or S. cerevisiae.12,13
Artemisinin is a sesquiterpene lactone endoperoxide, isolated
from the sweet wormwood plant (Artemisinin annua), which
is highly effective against multi-drug resistant strains of the
malaria parasite Plasmodium falciparum. The relative structural
complexity of artemisinin, makes its total synthesis challenging,
and its production by traditional methods costly.14 The conversion
of artemisinic acid to artemisinin in contrast, is efﬁcient and cost
effective,15 therefore the microbial synthesis of artemisinic acid
should reduce the production costs of artemisinin to make it
affordable to those in the developing world.
The ﬁrst step towards artemisinic acid is the introduction of
the amorphadiene synthase gene from A. annua into a suitable
host (E. coli12 or S. cerevisiae13). This results in the production
of amorphadiene from farnesyl pyrophosphate (FPP), but the
increase in demand on FPP results in low yields. Improving
the amount of amorphadiene produced required modifying the
biosynthetic pathways in the host to increase FPP levels. This
was achieved by up-regulating the several genes responsible for
FPP biosynthesis, and down-regulating an enzyme converting
FPP to sterols. With amorphadiene production optimised, its
conversion to artemisinic acid was achieved in one step using a
novel cytochrome p450 and its redox partner fromA. annua, which
catalyses the three-step oxidation reaction within the host strain
(Fig. 3). This resulted in a strain of E. coli producing artemisinic
acid de novo at levels exceeding 300 mg L-1,16 and transgenic
yeast producing artemisinic acid at 115 mg L-1.13 Artemisinic
acid is readily isolated from fermentation tanks and converted to
artemisinin. This process has proved so efﬁcient that it is being
developed for the large-scale production of artemisinin and is
Fig. 3 Semi-synthetic production of Artemisinin. The gene coding for
amorphadiene synthase (ADS) is introduced into the organism, and
converts FPP to amorphadiene. Amprphadiene is converted to artemisinic
acid by a novel p450 oxidase and its redox partner (cpr) also introduced
into the organism. Artemisinic acid is puriﬁed from the fermentation tanks
and converted to artemisinin using established chemical steps.
expected to dramatically reduce the cost of an adult course of
the drug (currently around $2.20).
Another area where synthetic biology has the potential to
make a signiﬁcant contribution is the microbial production of
biofuels. This approach has the potential to have a dramatic
impact, given the increasing energy costs and the need for
renewable, environmentally friendly fuels. Metabolic engineering
of E. coli and S. cerevisiae for the production of n-butanol17,18 are
recent examples of this promising approach. Although still in its
infancy, there is much potential for well-characterized biological
components that can be combined with a suitable chassis to
develop “microbial factories” capable of biosynthesizing complex
chemicals and compounds, in higher yields and shorter times than
traditional methods.
Synthetic genomes
This branch of synthetic biology is focused on the chemical
synthesis of minimal genome organisms and artiﬁcial life in the
laboratory. This aim has been greatly advanced by recent progress
in DNA synthesis and sequencing technology. Yet, despite the
lowered cost of DNA synthesis and sequencing, there are several
technical barriers to the synthesis of chromosome-sized stretches
of DNA. Current technology allows for the accurate, direct
synthesis of a few hundred base pairs; the synthesis of longer
fragments requires a combined chemical–biochemical approach,
where oligonucleotides (of around 100 bases) are synthesized,
combined and ligated to give larger fragments of DNA. This cycle
is repeated to yield ever-larger fragments of DNA, and has been
used for the construction of viral and bacterial chromosomes.19–21
An early example was the synthesis of the poliovirus cDNA,
which upon transcription by RNA polymerase, and translation
in a cell free extract resulted in the de novo synthesis of infec-
tious poliovirus.19 The genome of poliovirus (7440 RNA bases)
was constructed by assembling puriﬁed DNA oligonucleotides
(average length of 69 nucleotides) of plus and minus polarity
with overlapping complimentary sequences at each end. These
were combined into 400–600 base pair segments (the overlapping
regions will align, due to the natural base-pairing of DNA) and
ligated into a plasmid vector. These vectors were sequenced to
ensure the ﬁdelity of the gene fragments and their correct assembly.
These DNA fragments were combined (again by overlapping
complimentary regions) to give three overlappingDNA fragments
of 3026, 1895 and 2682 base pairs each. Combining these three
fragments resulted in the full-length cDNA of poliovirus, which
was converted to de novo poliovirus RNAby transcription with T7
RNA polymerase.19 A more efﬁcient method was reported shortly
after, which was used for the synthesis of the fX174 bacteriophage
genome (5386 base pairs).21 This methodology has now been used
for the synthesis of a bacterial genome (Mycoplasma genitalium)
consisting of 582 970 base pairs.20,22 The synthetic genome was
identical to the wild-type, except for the insertion of an antibiotic
marker within a gene associated with adhesion to mammalian
cells (GM408), to block pathogenicity. The same group had
demonstrated “genome transplantation” in an earlier paper;23
completely replacing the genome of Mycoplasma capricolum with
intact genomic DNA fromMycoplasma mycoides. It was therefore
hoped that the synthetic genome of M. genitalium could be
transplanted in a similar way, thus installing and booting up the
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synthetic genome within a bacterial chassis. This has so far proved
elusive, for reasons that are not clear.
Although there has been a signiﬁcant reduction in the cost of
DNA synthesis over the past decade, more robust methods for the
synthesis of long oligonucleotides are still needed, and this is an
area to which chemists can make signiﬁcant contributions. New,
more efﬁcient DNA coupling reactions would enable the rapid
assembly of very large fragments of DNA, and are essential to
fully realising the promises of synthetic biology.
Minimal genome chassis
The ability of most host organisms to detect, inactivate and
eject foreign DNA through a variety of built in defence mech-
anisms counteracts the stability of the DNA introduced into
the chassis. A bacterial strain with a reduced genome that
has its unwanted functions removed, would not only better
maintain foreign gene networks; it would also better tolerate the
metabolic burden of producing additional introduced enzymes
and metabolites. Recently reported genome-reduced strains of
E. coli (constructed by rational design) take important steps
towards this goal,24 selectively eliminating nonessential genes
and those with unwanted functions. This leads to strains with
around 15% of their genome eliminated, with comparable growth
rates to the wild-type organism, that were able to propagate and
maintain recombinant genes and plasmids with higher accuracy.
The long-term goal is a minimal genome organism optimised for
synthetic biology through dedicated insertion sites and markers.
The minimal pathway-footprint of the organism would allow
the inserted functions/pathways to proceed more effectively (less
resources required for maintaining organism) and potentially less
interference of the biological pathways with the inserted ones.
A minimal genome organism will not only serve as a potentially
ideal chassis, but may also be used to study evolution and the
origins of life. The construction of such an organism can be
approached from two directions: subtracting genes from an ex-
isting organism (as discussed above),24 or the in vitro construction
of a living system from components associated with life (DNA,
RNA, proteins) and non-natural material.25 The relatively broad
deﬁnition of what constitutes life26 allows a great deal of creativity
and ﬂexibility in this approach. The majority of the research so far
has involved encapsulating components within lipid vesicles27 or
water–oil emulsions,28 with examples of vesicles constructed that
contain cell extracts, enzymes or nucleic acids that are able to carry
out basic biological functions, such as protein expression or DNA
replication. The fragility of the minimal cells and its dependence
on specialized, non-standard feeding material provides a built-in
safety feature that should prevent their survival and replication
outside the laboratory.
The second wave
The ﬁrst wave of synthetic biology has been multifaceted in its
deﬁnition, encompassing a variety of areas and disciplines, each
with different immediate goals. It has promised much, and as a
result has enthused many people for the ﬁeld. We are close to the
beginning of the second phase of synthetic biology in which the
basic parts andmodules of the ﬁrst wavewill be combined together
to create systems-level circuitry. There are signiﬁcant challenges
associated with creating larger functional systems, for example,
there is relatively little known about the complexity of biological
systems and the response of the system to the introduction of
new pathways. The stochastic nature of biochemical reactions
also introduces signiﬁcant genetic noise into biological systems,
which seems at odds with attempts to create predictable, robust
systems. We are just beginning to unravel and understand the role
of noise in cellular processes; it may be that eliminating noise from
biological systems is impossible and instead components need to
be generated that are resistant to cellular noise and epigenetic
variations. Circadian rhythms for example tend to be highly
resistant to noise, and as our understanding of these processes
improves, so will our ability to emulate their robustness when
designing new components.
For the synthetic biology community to continue its rapid
growth and for the term to become more than just the latest
buzzword, it needs to engage and enthuse young scientists to
ensure injection of new ideas into the ﬁeld and evolution of the old
ones. The synthetic biology community has developed a fantastic
way to achieve these goals through the International Genetically
Engineered Machine (iGEM) competition. Since 2004, teams of
undergraduates have gathered every autumn at Massachusetts
Institute of Technology for the iGEM jamboree, to showcase
their synthetic biology summer projects. The students use a
standard set of BioBricks (biological components and parts in
a standardised vector that contains the same restriction sites
to allow easy cloning) supplied to them in late spring as their
building blocks. The competition has grown rapidly, from just 5
teams in 2004 to 84 international teams (more than 800 students)
in 2008, and 112 teams registered for the 2009 competition.
Many of the undergraduates tend to be ﬁrst or second years,
and therefore have a limited scientiﬁc background; nonetheless,
iGEM has resulted in the conception and construction of several
exciting devices, such as bacterial sensors and switches that have
led to full-scale laboratory projects (see the iGEM website for
speciﬁc details of projects). More importantly, iGEM serves as
a motivating teaching method and an exceptional way to enthuse
young scientists for synthetic biology, ensuring the rapid expansion
of the ﬁeld over the coming years.
There is tremendous potential in the second wave of synthetic
biology, and if successful, it will redeﬁne the way we tackle
some of the biggest challenges faced by humanity. The ability to
engineer life, to rapidly and easily synthesize and construct viral
and bacterial genomes and to synthesize artiﬁcial living systems
presents several unique bioethical and biosafety issues.29 When
one considers that the products of the second wave of synthetic
biology will be most effective when deployed in living systems and
in the general ecosystem, a wide variety of ethical questions and
objections may be raised. A detailed discussion of these issues
is beyond the scope of this review; however, it is important that
scientists are fully engaged and actively involved in all aspects of
such discussions, to ensure policy makers and the public are aware
of the promise and possibility of synthetic biology, and have a
realistic and balanced view of the potential risks.
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